IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of “Moderate Buy” from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $231.80.

Several research firms have issued reports on IQV. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Morgan Stanley set a $240.00 target price on shares of IQVIA in a research report on Wednesday, February 11th. Jefferies Financial Group cut their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Truist Financial decreased their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st.

IQVIA Trading Up 5.0%

Shares of NYSE:IQV opened at $179.09 on Monday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a market capitalization of $30.39 billion, a price-to-earnings ratio of 22.79, a PEG ratio of 1.72 and a beta of 1.40. IQVIA has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a 50 day moving average price of $212.19 and a 200 day moving average price of $208.13.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts anticipate that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Hedge funds have recently bought and sold shares of the business. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the 4th quarter worth $25,000. Physician Wealth Advisors Inc. boosted its holdings in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. International Assets Investment Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Finally, CrossGen Wealth LLC bought a new position in IQVIA during the fourth quarter valued at about $28,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.